PTRS Spotlight: The Best-Positioned Bet Isnt Oral When we apply Intelligencias PTRS (Probability of Technical and Regulatory Success) framework, the most promising GLP-1adjacent asset that is not already approved is CagriSemaa fixed-dose combination of cagrilintide (amylin analogue) and semaglutide, delivered as a once-weekly subcutaneous injection
Where It Works Treatment can be applied to any area of excess fat on the body
, BPC 157 NF-B
However, many patients experience the greatest benefits when both are used together, especially when protocols are customized based on age, symptoms, lab results, and health history
Both studies involved patients without diabetes who had a BMI of 30 or higher, or 27 or higher with a weight-related condition
In the rodents, higher doses went with lower body weight and blood sugar, and the glucagon pathway went with less liver fat